BibTex RIS Kaynak Göster

MİDE KANSERİ

Yıl 2004, Cilt: 10 Sayı: 1, 1 - 8, 01.03.2004

Bülent Karabulut Erdem Göker

Anahtar Kelimeler

Mide Kanser

Kaynakça

  • Gunderson LL, Donohue JH, Burch PA: Stomach, in Abeloff MD, Armitage JO, Lichter AS, et al: Clinical Oncology. New York, NY, Chuschill Livingstone, pp:1209-1241, 1995.
  • Green Lee RT, Murray T, Bolden S, et al. Cancer Statistics 2000. CA Cancer J Clin 50:7-33, 2000.
  • Wu-Williams AH, Yu MC, Mack TM. Life style, work, place, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res 50:2569-2576, 1990.
  • Macdonald JS, Hill MC, Roberts IM. Gastric cancer: Epidemiology, pathology, detection and staging, in Ahlgren JD, Macdonald JS (eds): Gastrointestinal Oncology. Philadelphia, PA, J.B Lippincott, pp:151-158, 1992.
  • Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol 12 (1): 11-8, 1985.
  • Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 106 (2): 222-6, 1999.
  • Fenoglio-Preiser CM, Noffsinger AE, Belli J, et al. Pathologic and phenotypic features of gastric cancer. Semin Oncol 23 (3): 306, 1996.
  • Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (10): 1287-9, 1991.
  • Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228 (4): 449-61, 1998.
  • Nakamura K, Ueyama T, Yao T, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 70 (5): 1030-7, 1992.
  • Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 89 (7): 1418-24, 2000.
  • Fine G, Chan K: Alimentary tract. In: Kissane JM, ed. Anderson's Pathology. Vol 2. 8th ed. Saint Louis, Mo: CV Mosby, 1985, pp 1055-1095.
  • Maehara Y, Sakaguchi Y, Moriguchi S, et al. Signet ring cell carcinoma of the stomach. Cancer 69 (7): 1645-50, 1992.
  • Stomach. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 106.
  • Roder JD, Böttcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 82 (4): 621-31, 1998.
  • Ichikura T, Tomimatsu S, Uefuji K, et al. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer 86 (4): 553-8, 1999.
  • Bonenkamp JJ, Hermans J, Sasako M. Extended lymph-node dissection for gastric cancer. N Engl J Med, 340:908-914, 1999.
  • Kodama Y, Sugimachi K, soejima K et al. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 5:241-248, 1981.
  • Vezerdis MP, Wanebo HJ: Gastric cancer Surgical approach. In Gastrointestinal Oncology, eds Ahlgren JD ve Macdonald JS. Lippincott, Philadelphia, PA 159-170, 1992.
  • Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg, 75:110- , 1998.
  • Robertson CS, Chung SC, Woods SDS, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg, 220:176-182, 1994.
  • Bunt AM, Hermans J, Smit VT: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol, 13:19-25, 1995.
  • Hermans J, Bonenkamp JJ, Boon MC et al.: Adjuvant therapy after curative resection for gastric cancer. Meta-analysis of randomized trials. J Clin Oncol 11:1441-1447, 1993.
  • Macdonald JS, Fleming TR, Peterson RF, et al.: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group Study. Ann Surg Oncol, 2:488-494, 1995.
  • Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients: Revisiting a meta-analysis of randomized trials. Eur J Cancer, 35:1059-1064, 1999.
  • Macdonald JS, Smalley SR, Benedetti J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345:725-730, 2001.
  • Vanhoefer U, Rougier P, Wilke H, et al.: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 (14): 2648-57, 2000.
  • Comis RL, Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treat Rev 1(3): 221-238, 1974.
  • Cullinan SA, Moertel CG, Fleming TR, et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253 (14): 2061-7, 1985.
  • MacDonald JS, Schein PS, Woolley PV, et al.: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93 (4): 533-6, 1980.
  • Douglass HO Jr, Lavin PT, Goudsmit A, et al.: An Eastern Cooperative Oncology Group evaluation of combinations of methyl- CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2 (12): 81, 1984.
  • Moertel CG, Rubin J, O'Connell MJ, et al.: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4 (7): 1053-7, 1986.
  • Waters JS, Norman A, Cunningham D, et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80 (1-2): 269-72, 1999.
  • Ajani JA, Ota DM, Jackson DE: Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer (1 Suppl): 260-5, 1991.
  • Cascinu S, Labianca R, Alessandroni P, et al.: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15 (11): 3313-9, 1997.
  • Ohtsu A, Shimada Y, Shirao K, et al.: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (1): 54-9, 2003.
  • Preusser P, Wilke H, Achterrath W et al.: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol, 7:1310-1317, 1989.
  • Kelsen D, Atiq OT, Saltz L, et al.: FAMTX versus etoposide, doxorubicin, and cisplatin: A random asignment trial in gastric cancer. J Clin Oncol, 10:541-548, 1992.
  • Wils JA, Klein HO, Wagener DJ, et al.: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin – A step ahead in the treatment of advanced gastric cancer: A trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol, 9:827-831, 1991.
  • Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cicplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagealgastric cancer. J Clin Oncol, 15:261-267, 1997.
  • Ilson DH, Saltz L, Enzinger P et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol, 17:3270-3725, 1999.
  • Kettner E, Ridwelski K, Keilholz U, et al.: Docetakxel and cisplatin combination chemotherapy for advanced gastric cancer: Results of two phase II studies. Proc Am Soc Clin Oncol, 20:165A, 2001.
  • Green PH, O'Toole KM, Slonim D, et al.: Increasing incidence and excellent survival of patients with early gastric cancer: experience in a United States medical center. Am J Med 85 (5): 658-61, 1988.
  • Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 230 (2): 170-8, 1999. ÖZGEÇMİŞ Prof. Dr. Erdem GÖKER Kişisel Bilgiler : 05.1961 Tarihinde İzmir’de Doğmuştur. Evlidir. Mesleki Bilgiler
  • Ege Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Onkoloji Bilim Dalı 2000
  • Ege Üniversitesi Tıp Fakültesi Fakülte Kurulu Üyesi : Ege Üniversitesi İlaç Araştırma – Geliştirme Ve Farmakokinetik Araştırmalar Merkezi Müdür Yardımcısı 2000
  • Ege Üniversitesi Kanser Araştırma Ve Uygulama Merkezi Yönetim Kurulu Üyesi : Tıbbi Onkoloji Uzmanı ( 9 Eylül Üniversitesi Tıp Fakültesi Hematoloji-Onkoloji Bilim Dalı) 1995
  • Memorial Sloan-Kettering Kanser Merkezi, New York, ABD Hematoloji-Onkoloji Yandal İhtisası Slon-Kettering Enstitüsü Moleküler Farmakoloji Programı : İç Hastalıkları Uzmanı 1992
  • Ege Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dali Araştırma Görevlisi 1987
  • Çorum Kargı Merkez Sağlık Ocağı Tabibliği 1985
  • Hacettepe Üniversitesi Tıp Fakültesi 1978
  • İzmir Özel Türk Koleji 1972

GASTRIC CANCER

Yıl 2004, Cilt: 10 Sayı: 1, 1 - 8, 01.03.2004

Bülent Karabulut Erdem Göker

Anahtar Kelimeler

Gastric Cancer

Kaynakça

  • Gunderson LL, Donohue JH, Burch PA: Stomach, in Abeloff MD, Armitage JO, Lichter AS, et al: Clinical Oncology. New York, NY, Chuschill Livingstone, pp:1209-1241, 1995.
  • Green Lee RT, Murray T, Bolden S, et al. Cancer Statistics 2000. CA Cancer J Clin 50:7-33, 2000.
  • Wu-Williams AH, Yu MC, Mack TM. Life style, work, place, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res 50:2569-2576, 1990.
  • Macdonald JS, Hill MC, Roberts IM. Gastric cancer: Epidemiology, pathology, detection and staging, in Ahlgren JD, Macdonald JS (eds): Gastrointestinal Oncology. Philadelphia, PA, J.B Lippincott, pp:151-158, 1992.
  • Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol 12 (1): 11-8, 1985.
  • Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 106 (2): 222-6, 1999.
  • Fenoglio-Preiser CM, Noffsinger AE, Belli J, et al. Pathologic and phenotypic features of gastric cancer. Semin Oncol 23 (3): 306, 1996.
  • Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (10): 1287-9, 1991.
  • Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228 (4): 449-61, 1998.
  • Nakamura K, Ueyama T, Yao T, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 70 (5): 1030-7, 1992.
  • Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 89 (7): 1418-24, 2000.
  • Fine G, Chan K: Alimentary tract. In: Kissane JM, ed. Anderson's Pathology. Vol 2. 8th ed. Saint Louis, Mo: CV Mosby, 1985, pp 1055-1095.
  • Maehara Y, Sakaguchi Y, Moriguchi S, et al. Signet ring cell carcinoma of the stomach. Cancer 69 (7): 1645-50, 1992.
  • Stomach. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 106.
  • Roder JD, Böttcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 82 (4): 621-31, 1998.
  • Ichikura T, Tomimatsu S, Uefuji K, et al. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer 86 (4): 553-8, 1999.
  • Bonenkamp JJ, Hermans J, Sasako M. Extended lymph-node dissection for gastric cancer. N Engl J Med, 340:908-914, 1999.
  • Kodama Y, Sugimachi K, soejima K et al. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 5:241-248, 1981.
  • Vezerdis MP, Wanebo HJ: Gastric cancer Surgical approach. In Gastrointestinal Oncology, eds Ahlgren JD ve Macdonald JS. Lippincott, Philadelphia, PA 159-170, 1992.
  • Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg, 75:110- , 1998.
  • Robertson CS, Chung SC, Woods SDS, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg, 220:176-182, 1994.
  • Bunt AM, Hermans J, Smit VT: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol, 13:19-25, 1995.
  • Hermans J, Bonenkamp JJ, Boon MC et al.: Adjuvant therapy after curative resection for gastric cancer. Meta-analysis of randomized trials. J Clin Oncol 11:1441-1447, 1993.
  • Macdonald JS, Fleming TR, Peterson RF, et al.: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group Study. Ann Surg Oncol, 2:488-494, 1995.
  • Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients: Revisiting a meta-analysis of randomized trials. Eur J Cancer, 35:1059-1064, 1999.
  • Macdonald JS, Smalley SR, Benedetti J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345:725-730, 2001.
  • Vanhoefer U, Rougier P, Wilke H, et al.: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 (14): 2648-57, 2000.
  • Comis RL, Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treat Rev 1(3): 221-238, 1974.
  • Cullinan SA, Moertel CG, Fleming TR, et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253 (14): 2061-7, 1985.
  • MacDonald JS, Schein PS, Woolley PV, et al.: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93 (4): 533-6, 1980.
  • Douglass HO Jr, Lavin PT, Goudsmit A, et al.: An Eastern Cooperative Oncology Group evaluation of combinations of methyl- CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2 (12): 81, 1984.
  • Moertel CG, Rubin J, O'Connell MJ, et al.: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4 (7): 1053-7, 1986.
  • Waters JS, Norman A, Cunningham D, et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80 (1-2): 269-72, 1999.
  • Ajani JA, Ota DM, Jackson DE: Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer (1 Suppl): 260-5, 1991.
  • Cascinu S, Labianca R, Alessandroni P, et al.: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15 (11): 3313-9, 1997.
  • Ohtsu A, Shimada Y, Shirao K, et al.: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (1): 54-9, 2003.
  • Preusser P, Wilke H, Achterrath W et al.: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol, 7:1310-1317, 1989.
  • Kelsen D, Atiq OT, Saltz L, et al.: FAMTX versus etoposide, doxorubicin, and cisplatin: A random asignment trial in gastric cancer. J Clin Oncol, 10:541-548, 1992.
  • Wils JA, Klein HO, Wagener DJ, et al.: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin – A step ahead in the treatment of advanced gastric cancer: A trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol, 9:827-831, 1991.
  • Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cicplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagealgastric cancer. J Clin Oncol, 15:261-267, 1997.
  • Ilson DH, Saltz L, Enzinger P et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol, 17:3270-3725, 1999.
  • Kettner E, Ridwelski K, Keilholz U, et al.: Docetakxel and cisplatin combination chemotherapy for advanced gastric cancer: Results of two phase II studies. Proc Am Soc Clin Oncol, 20:165A, 2001.
  • Green PH, O'Toole KM, Slonim D, et al.: Increasing incidence and excellent survival of patients with early gastric cancer: experience in a United States medical center. Am J Med 85 (5): 658-61, 1988.
  • Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 230 (2): 170-8, 1999. ÖZGEÇMİŞ Prof. Dr. Erdem GÖKER Kişisel Bilgiler : 05.1961 Tarihinde İzmir’de Doğmuştur. Evlidir. Mesleki Bilgiler
  • Ege Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Onkoloji Bilim Dalı 2000
  • Ege Üniversitesi Tıp Fakültesi Fakülte Kurulu Üyesi : Ege Üniversitesi İlaç Araştırma – Geliştirme Ve Farmakokinetik Araştırmalar Merkezi Müdür Yardımcısı 2000
  • Ege Üniversitesi Kanser Araştırma Ve Uygulama Merkezi Yönetim Kurulu Üyesi : Tıbbi Onkoloji Uzmanı ( 9 Eylül Üniversitesi Tıp Fakültesi Hematoloji-Onkoloji Bilim Dalı) 1995
  • Memorial Sloan-Kettering Kanser Merkezi, New York, ABD Hematoloji-Onkoloji Yandal İhtisası Slon-Kettering Enstitüsü Moleküler Farmakoloji Programı : İç Hastalıkları Uzmanı 1992
  • Ege Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dali Araştırma Görevlisi 1987
  • Çorum Kargı Merkez Sağlık Ocağı Tabibliği 1985
  • Hacettepe Üniversitesi Tıp Fakültesi 1978
  • İzmir Özel Türk Koleji 1972
Toplam 52 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Research Article
Yazarlar

Bülent Karabulut Bu kişi benim

Erdem Göker Bu kişi benim

Yayımlanma Tarihi 1 Mart 2004
Yayımlandığı Sayı Yıl 2004 Cilt: 10 Sayı: 1

Kaynak Göster

APA Karabulut, B., & Göker, E. (2004). MİDE KANSERİ. İzmir Eğitim Ve Araştırma Hastanesi Tıp Dergisi, 10(1), 1-8.
AMA Karabulut B, Göker E. MİDE KANSERİ. İzmir EAH Tıp Der. Mart 2004;10(1):1-8.
Chicago Karabulut, Bülent, ve Erdem Göker. “MİDE KANSERİ”. İzmir Eğitim Ve Araştırma Hastanesi Tıp Dergisi 10, sy. 1 (Mart 2004): 1-8.
EndNote Karabulut B, Göker E (01 Mart 2004) MİDE KANSERİ. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 10 1 1–8.
IEEE B. Karabulut ve E. Göker, “MİDE KANSERİ”, İzmir EAH Tıp Der, c. 10, sy. 1, ss. 1–8, 2004.
ISNAD Karabulut, Bülent - Göker, Erdem. “MİDE KANSERİ”. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 10/1 (Mart 2004), 1-8.
JAMA Karabulut B, Göker E. MİDE KANSERİ. İzmir EAH Tıp Der. 2004;10:1–8.
MLA Karabulut, Bülent ve Erdem Göker. “MİDE KANSERİ”. İzmir Eğitim Ve Araştırma Hastanesi Tıp Dergisi, c. 10, sy. 1, 2004, ss. 1-8.
Vancouver Karabulut B, Göker E. MİDE KANSERİ. İzmir EAH Tıp Der. 2004;10(1):1-8.